

IMPORTANT INFORMATION SHORTAGE NOTIFICATION

Ozempic Shortage

As of December 14, 2022, the American Society of Health-System Pharmacists (ASHP) and the U.S. Food and Drug Administration (FDA) websites list shortages of both semaglutide brands--**Wegovy** and **Ozempic**--as well as the dulaglutide brand of **Trulicity**.

Due to unprecedented demand and short-term manufacturing issues all Ozempic strengths are on intermittent backorder and the manufacturers are releasing product as it becomes available. **As such, MILA members are encouraged to speak with their physician** to determine if one of the preferred GLP-1 formulary options (e.g., **Rybelsus** or **Victoza**) is an appropriate clinical alternative at this time.

It is important to note there continues to be preferred formulary alternatives available in the market. For Ozempic and Trulicity, there are several other options listed on the CVS Caremark formulary, for example, and as mentioned above, Rybelsus or Victoza. Additionally, **Saxenda** continues to be an available preferred alternative to Wegovy.

CVS Health is a major purchaser of prescription drugs in the United States, and typically has access to supply when made available by the manufacturer, however limitations can occur due to manufacture shortages. These challenges are not exclusive to CVS Health, who continues to work diligently to maintain medication supplies for MILA members.